The adaptor protein VEPH1 interacts with the kinase domain of ERBB2 and impacts EGF signaling in ovarian cancer cells

被引:3
|
作者
Kollara, Alexandra [1 ,3 ]
Burt, Brian D. [1 ,2 ,5 ]
Ringuette, Maurice J. [2 ]
Brown, Theodore J. [1 ,3 ,4 ]
机构
[1] Sinai Hlth Syst, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[2] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON, Canada
[3] Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON, Canada
[4] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, 60 Murray St, 6-10016-2, Toronto, ON M5T 3L9, Canada
[5] Univ Hlth Network, Campbell Family Inst Breast Canc Res, Princess Margaret Canc Ctr, Tumor Immunotherapy Program, Toronto, ON, Canada
关键词
EGF; ERBB2; ERK1; 2; Ovarian cancer; VEPH1; AKT; MAMMALIAN TARGET; RAPAMYCIN MTOR; BRAF MUTATION; RAF KINASES; INHIBITION; BINDING; PHOSPHORYLATION; EXPRESSION; DISCOVERY; THERAPY;
D O I
10.1016/j.cellsig.2023.110634
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Upregulation of ERBB2 and activating mutations in downstream KRAS/BRAF and PIK3CA are found in several ovarian cancer histotypes. ERBB2 enhances signaling by the ERBB family of EGF receptors, and contains docking positions for proteins that transduce signaling through multiple pathways. We identified the adaptor protein ventricular zone-expressed pleckstrin homology domain-containing protein 1 (VEPH1) as a potential interacting partner of ERBB2 in a screen of proteins co-immunoprecipitated with VEPH1. In this study, we confirm a VEPH1 -ERBB2 interaction by co-immunoprecipitation and biotin proximity labelling and show that VEPH1 interacts with the juxtamembrane-kinase domain of ERBB2. In SKOV3 ovarian cancer cells, which bear a PIK3CA mutation and ERBB2 overexpression, ectopic VEPH1 expression enhanced EGF activation of ERK1/2, and mTORC2 acti-vation of AKT. In contrast, in ES2 ovarian cancer cells, which bear a BRAFV600E mutation with VEPH1 amplifi-cation but low ERBB2 expression, loss of VEPH1 expression enabled further activation of ERK1/2 by EGF and enhanced EGF activation of AKT. VEPH1 expression in SKOV3 cells enhanced EGF-induced cell migration consistent with increased Snail2 and decreased E-cadherin levels. In comparison, loss of VEPH1 expression in ES2 cells led to decreased cell motility independent of EGF treatment despite higher levels of N-cadherin and Snail2. Importantly, we found that loss of VEPH1 expression rendered ES2 cells less sensitive to BRAF and MEK inhi-bition. This study extends the range of adaptor function of VEPH1 to ERBB2, and indicates VEPH1 has differ-ential effects on EGF signaling in ovarian cancer cells that may be influenced by driver gene mutations.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells
    Ana Maria Tari
    Mien-Chie Hung
    Kaiyi Li
    Gabriel Lopez-Berestein
    Oncogene, 1999, 18 : 1325 - 1332
  • [42] Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells
    Tari, AM
    Hung, MC
    Li, KY
    Lopez-Berestein, G
    ONCOGENE, 1999, 18 (06) : 1325 - 1332
  • [43] Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90
    Xu, WP
    Mimnaugh, E
    Rosser, MFN
    Nicchitta, C
    Marcu, M
    Yarden, Y
    Neckers, L
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (05) : 3702 - 3708
  • [44] ErbB2 Induces Notch1 Activity and Function in Breast Cancer Cells
    Lindsay, Jaime
    Jiao, Xuanmao
    Sakamaki, Toshiyuki
    Casimiro, Mathew C.
    Shirley, Lawrence A.
    Tran, Thai H.
    Ju, Xiaoming
    Liu, Manran
    Li, Zhiping
    Wang, Chenguang
    Katiyar, Sanjay
    Rao, Mahadev
    Allen, Kathleen G.
    Glazer, Robert I.
    Ge, Changhui
    Stanley, Pamela
    Lisanti, Michael P.
    Rui, Hallgeir
    Pestell, Richard G.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2008, 1 (02): : 107 - 115
  • [45] Peptides for Dual Targeting of ErbB1 and ErbB2: Blocking EGFR Cell Signaling Transduction Pathways for Cancer Chemotherapy
    Patnaik, Sunil Kumar
    Swaroop, Akey Krishna
    Nagarjuna, Palathoti
    Nanjan, Moola Joghee
    Chandrasekar, Moola Joghee Nanjan
    CURRENT MOLECULAR PHARMACOLOGY, 2024, 17
  • [46] A novel mutation in the tyrosine kinase domain of ErbB2: molecular and proteomic investigation of its role in breast cancer invasion
    O'Hara, J.
    Kast, J.
    CANCER RESEARCH, 2012, 72
  • [47] Evaluation of AZD8931, an Equipotent Inhibitor of erbB1, erbB2, and erbB3 Receptor Signaling, on Ligand Stimulated Breast Cancer Cell Lines with Differing Levels of erbB2 Expression
    Marshall, G.
    Klinowska, T. C. M.
    Mills, E. A.
    Ogilvie, D.
    Hickinson, D. M.
    Speake, G.
    CANCER RESEARCH, 2009, 69 (24) : 784S - 785S
  • [48] Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
    Greulich, Heidi
    Kaplan, Bethany
    Mertins, Philipp
    Chen, Tzu-Hsiu
    Tanaka, Kumiko E.
    Yun, Cai-Hong
    Zhang, Xiaohong
    Lee, Se-Hoon
    Cho, Jeonghee
    Ambrogio, Lauren
    Liao, Rachel
    Imielinski, Marcin
    Banerji, Shantanu
    Berger, Alice H.
    Lawrence, Michael S.
    Zhang, Jinghui
    Pho, Nam H.
    Walker, Sarah R.
    Winckler, Wendy
    Getz, Gad
    Frank, David
    Hahn, William C.
    Eck, Michael J.
    Mani, D. R.
    Jaffe, Jacob D.
    Carr, Steven A.
    Wong, Kwok-Kin
    Meyerson, Matthew
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (36) : 14476 - 14481
  • [49] The EGF domains of MUC4 oncomucin interact with ErbB2 and mediate with ErbB2 and mediate tumorigenic activity of cancer cells tumorigenic activity of cancer cells represent new potential therapeutic represent new potential therapeutic targets
    Stoup, Nicolas
    Liberelle, Maxime
    Schulz, Celine
    Vasseur, Romain
    Magnez, Romain
    Thuru, Xavier
    Melnyk, Patricia
    Renault, Nicolas
    Jonckheere, Nicolas
    Lebegue, Nicolas
    Van Seuningen, Isabelle
    FASEB JOURNAL, 2021, 35
  • [50] Clinicopathological Features of Insertion Mutations in Kinase Domain of EGFR and ERBB2 in Non-Small-Cell Lung Cancer
    Zhao, Ruiying
    Xiang, Chan
    Zhu, Lei
    Shao, Jinchen
    Zhao, Jikai
    Guo, Lianying
    Ma, Shengji
    Yu, Anbo
    Han, Yuchen
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1833 - 1834